Abstract
Results: Dose dependent antitumoral activity was observed in both animals models. FGFR inhibition resulted in dynamic modulation of circulating FGF23 levels, as well as inhibition of FGFR downstream signaling in tumor tissue. Frequency of administration impacted on efficacy and potential toxicity. The PKPD relationship was explored. Conclusions: Debio 1347 administration resulted in a dose-dependent reduction in tumor growth in both animal models, displaying either a FGFR fusion or amplification. These results suggest that Debio 1347 will provide therapeutic opportunities for patients who have FGFR genetic alterations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
